Lung Cancer | Specialty

Rizvi Highlights Impact of Immunotherapy and Next Steps NSCLC

March 12th 2019

Naiyer A. Rizvi, MD, highlights the progress made with immunotherapy in patients with NSCLC and shed light on where further research needs to go to move the needle forward.

Dr. Naidoo on Considerations for Managing irAEs in NSCLC

March 11th 2019

Jarushka Naidoo, MBBCh, assistant professor of oncology, Johns Hopkins University, discusses considerations for managing immune-related adverse events in patients with non–small cell lung cancer.

Dr. Padda on Novel Combinations for EGFR+ NSCLC

March 9th 2019

Sukhmani Padda, MD, assistant professor of medicine, Stanford University Medical Center, member, Stanford Cancer Institute, discusses novel combinations in the treatment of patients with EGFR-positive non–small cell lung cancer.

Frontline Atezolizumab Regimen Approved in Europe for NSCLC

March 8th 2019

The European Commission has approved and granted marketing authorization to the frontline combination of atezolizumab, bevacizumab, paclitaxel, and carboplatin for the first-line treatment of patients with metastatic, nonsquamous non–small cell lung cancer.

Dr. Sabari Discusses the Utility of Liquid Biopsies in Lung Cancer

March 7th 2019

Joshua K. Sabari, MD, assistant professor, Department of Medicine, NYU Langone’s Perlmutter Cancer Center, discusses the utility of liquid biopsies in lung cancer.

Study Exclusion Criteria Limits Real-World Benefit of Immunotherapy in Lung Cancer

March 6th 2019

Mohammad Jahanzeb, MD, shares the challenges of real-world eligibility for immunotherapy in lung cancer and beyond.

Dr. Wakelee on Unmet Needs for Immunotherapy in NSCLC

March 6th 2019

Heather Wakelee, MD, associate professor of medicine, Stanford University Medical Center, discusses unmet needs for immunotherapy in the treatment of patients with non–small cell lung cancer.

EU Panel Backs Extended Pembrolizumab Dosing Schedule for Single-Agent Indications

March 5th 2019

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for a new extended dosing schedule for pembrolizumab for all of the PD-1 inhibitor’s monotherapy indications in the European Union.

Dr. Mix on Local Consolidative Therapy in Oligometastatic NSCLC

March 2nd 2019

Michael D. Mix, MD, assistant professor of radiation oncology at Upstate University Hospital, discusses the use of local consolidative therapy in patients with oligometastatic non–small cell lung cancer (NSCLC).

EU Panel Backs Lorlatinib for ALK+ NSCLC

March 1st 2019

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of lorlatinib for the treatment of adult patients with ALK-positive advanced non–small cell lung cancer whose disease has progressed after alectinib or ceritinib as the first ALK TKI, or crizotinib and at least one other ALK TKI.

Stereotactic Body Radiotherapy Shows Potential in Oligometastatic Cancer

March 1st 2019

An increasing amount of evidence shows that a proportion of patients with cancer found to have low-volume metastases at diagnosis see meaningful benefit from aggressive local therapy. Equally important, there have been no meaningful reductions in reported quality of life among patients receiving intensive local therapy, and a small percentage of patients appear to be cured with this strategy.

Dr. Jahanzeb on Immunotherapy in Elderly Patients With NSCLC

March 1st 2019

Mohammad Jahanzeb, MD, professor of clinical medicine, Hematology/Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses immunotherapy in the treatment of elderly patients with non–small cell lung cancer.

Study Validates Speed, Accuracy of Liquid Biopsies Identifying NSCLC Biomarkers

February 28th 2019

A liquid biopsy test detected all of the guideline-recommended biomarkers in newly diagnosed patients with metastatic non–small cell lung cancer at a similar rate but faster turnaround time to that of tissue genotyping.

A Game-Changing Year for NSCLC

February 26th 2019

Available Therapies for ALK-Rearranged NSCLC

February 26th 2019

Resistance Mechanisms in EGFR+ NSCLC

February 26th 2019

Osimertinib, the Standard for EGFR+ NSCLC

February 26th 2019

Molecular Testing for NSCLC in 2019

February 26th 2019

ADRIATIC Trial in Locally Advanced Small-Cell Lung Cancer

February 26th 2019

A Win for Small-Cell Lung Cancer: IMPOWER 133

February 26th 2019